Ivan R. Gonzalez: Interesting review of Treatment Sequences in Advanced EGFR-Mutated NSCLC

Ivan R. Gonzalez, Medical Oncologist at Comprehensive Oncology Center, Hospital Angeles Puebla, shared a post on X:

An interesting review of Treatment Sequences in Advanced EGFR-Mutated NSCLC:

-TKIs have revolutionized the evolution of advanced NSCLC with common EGFR mutation.
-Tumor heterogeneity and acquired resistance mechanisms are inevitable limits.
-Recent treatment combinations show better outcomes in progression-free survival.
-These advances come with more serious side effects compared to the current standard.
-New therapeutic options open up possibilities for various treatment sequences.
-It is essential to consider the clinical and biological profile, as well as the patient’s preferences.

This review proposes an overview of published and future advances in EGFR-mutated NSCLC and a management algorithm that considers the different first-line options.”

Treatment sequences in EGFR mutant advanced NSCLC

Autors: M. Wespiser, A. Swalduz, M. Pérol

Source: Ivan R. Gonzalez/X